BioLife Solutions, Inc. BLFS R2KR3KPHARMA

Q: What is the current share price of BioLife Solutions, Inc. (BLFS)?

As of 2026-09-07 16:24 PDT, BioLife Solutions, Inc. (BLFS) trades at $35.25 on NasdaqCM. Its 52-week range is $18.15 to $37.22.

Q: What is the market capitalisation of BLFS?

BioLife Solutions, Inc. (BLFS) has a market capitalisation of $1.72B on NasdaqCM.

Q: What is the P/E ratio of BLFS?

BLFS trades at a trailing price-to-earnings (P/E) ratio of -146.88. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 4.49.

Q: What is the return on equity (ROE) of BLFS?

BLFS has a return on equity (ROE) of -3.09%. Its return on capital employed (ROCE) is -4.34%.

Q: Is BLFS a good stock to buy?

This page provides a data-driven analysis of BioLife Solutions, Inc. (BLFS), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Healthcare · Medical Instruments & Supplies · United States

https://www.biolifesolutions.com

Company Profile ↓

$35.25

+37.27% 1Y

Mkt Cap$1.72B

P/E-146.88

P/B4.49

52W High$37.22

52W Low$18.15

Book Value$7.72

EPS (TTM)$-0.24

Company Overview

BioLife Solutions, Inc. develops, manufactures, and markets bioproduction products and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor Freeze Media that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; bioproduction products, such as human platelet lysates for cell expansion and CellSeal closed system vials that are used in CGT; CryoCase cryo-compatible transparent rigid containers for closed-system fill and retrieval, and automated cell processing machines; and the ThawSTAR line include automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags. The company also provides evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals. It markets and sells its products directly, as well as through third party distributors. The company was incorporated in 1987 and is headquartered in Bothell, Washington.

Why Investors Should Care

Steady Revenue Expansion

Revenue has grown at a 31.5% CAGR over the past five years.

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

Dec 2025 Revenue of $96.21M (+28.9% YoY); net profit $-4.59M.
Trailing 12 Months Year-on-year growth — revenue +24.7%.
5-Year Trend Long-term compounding — revenue CAGR 31.5%.

Growth & Price Performance

Compounded Sales Growth

5 Years:	31.50%
1 Year:	24.70%

Stock Price Performance

1 Year:	+37.27%
6 Months:	+77.49%
3 Months:	+32.27%
1 Month:	+3.89%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish

52-Week Range 90% of range

$18.15 $37.22

Trend Signals

Price vs 50-DMAAbove
Price vs 200-DMAAbove
RSI (14)53.06 · Neutral

Price Performance

1M+3.89%

3M+32.27%

6M+77.49%

1Y+37.27%

Auto-generated from price history and fundamentals; not investment advice.

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Period: Metric:

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

Compounding revenue at 31.5% over 5 years.
Generates positive free cash flow.
In a confirmed uptrend (50-DMA above 200-DMA).

CONS

No notable concerns flagged.

* The pros and cons are auto-generated from financial metrics.

Valuation

Stock P/E

-146.88

Industry PE

25.17

Forward P/E

106.82

PEG Ratio

15.09

Book Value

$7.72

Price to Book

4.49

P/S

16.66

EV/EBITDA

368.34

Dividend Yield

0.00%

Growth (CAGR)

Revenue 5Y

31.50%

Profit 5Y

Revenue (YoY)

24.70%

Earnings (YoY)

Profitability & Returns

ROCE

-4.34%

ROE

-3.09%

ROA

-0.09%

Profit Margin

-2.91%

Op Margin

0.10%

Gross Margin

63.76%

EPS (Latest Qtr)

$0.91

EPS (TTM)

$-0.24

Balance Sheet & Liquidity

Debt/Equity

3.99

Quick Ratio

5.15

Current Ratio

7.30

Debt

$14.86M

Total Assets

$447.49M

Current Assets

Working Capital

Ownership

Promoter Holding

2.42%

Chg in Prom Hold

0.05%

FII / Inst Holding

105.52%

Chg in FII Hold

0.02%

Financial Snapshot

Enterprise Value

$1.72B

Total Revenue (TTM)

$101.66M

EBITDA

$4.32M

Free Cash Flow

$6.39M

Operating Cash Flow

$17.90M

Shares Outstanding

48.86M

Gross Margin

63.76%

Payout Ratio

0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP $	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	BLFS BioLife Solutions, Inc. R2KR3KPHARMA	35.25	-146.88	$1.72B	0.00%	-4.34%	-3.09%	31.50%	-
2	LLY Eli Lilly and Company SPXR3KPHARMA	1,149.36	38.57	$1.02T	0.58%	-	102.29%	7.20%	11.41%
3	JNJ Johnson & Johnson SPXR3KPHARMA	275.23	31.97	$663.28B	2.09%	14.88%	25.74%	2.43%	4.76%
4	ABBV AbbVie Inc. SPXR3KPHARMA	256.46	72.45	$453.19B	2.84%	10.47%	-129.24%	1.75%	-29.06%
5	MRK Merck & Co., Inc. SPXR3KPHARMA	150.33	120.26	$371.29B	2.65%	-	34.70%	5.64%	10.01%
6	UNH UnitedHealth Group Incorporated SPXR3KPHARMA	397.14	25.54	$356.47B	2.33%	9.74%	14.15%	10.40%	5.43%
7	NVS Novartis AG PHARMA	159.99	24.20	$304.10B	3.03%	21.09%	30.35%	9.25%	26.22%
8	AZN AstraZeneca PLC NDXPHARMA	162.70	24.36	$252.33B	1.98%	15.97%	21.96%	9.82%	45.96%
9	AMGN Amgen Inc. NDXSPXR3KPHARMA	437.23	27.14	$235.98B	2.49%	13.95%	91.47%	5.51%	5.55%

Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric	Jun 2013	Sep 2013	Mar 2014	Jun 2014	Sep 2014	Mar 2015	Jun 2015	Sep 2015	Mar 2016	Jun 2016	Sep 2016	Mar 2017	Jun 2017	Sep 2017	Mar 2018	Jun 2018	Sep 2018	Mar 2019	Jun 2019	Sep 2019	Mar 2020	Jun 2020	Sep 2020	Mar 2021	Jun 2021	Sep 2021	Mar 2022	Jun 2022	Sep 2022	Mar 2023	Jun 2023	Sep 2023	Mar 2024	Jun 2024	Sep 2024	Mar 2025	Jun 2025	Sep 2025	Mar 2026	Jun 2026
Revenue	2.33M	2.17M	2.07M	1.21M	1.24M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gross Profit	828.44K	888.86K	903.39K	545.32K	588.39K	882.62K	818.65K	973.38K	1.08M	1.12M	1.21M	1.44M	1.60M	1.87M	2.45M	3.64M	3.69M	4.12M	4.74M	4.52M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	14.80M	-	-	17.50M	18.29M
Operating Income	-82.84K	-110.09K	-369.04K	-887.87K	-874.51K	-1.16M	-1.16M	-1.30M	-1.49M	-1.59M	-1.14M	-464.04K	-341.20K	-32.34K	140.00K	1.28M	1.20M	566.00K	747.00K	-772.00K	370.00K	44.00K	-1.25M	-981.00K	-4.55M	-11.16M	-7.97M	-76.56M	-11.74M	-13.61M	-10.63M	-15.47M	-3.29M	-1.31M	-418.00K	-499.00K	-16.64M	-89.00K	27.00K	1.70M
Net Income	-282.51K	-309.91K	-559.37K	-883.36K	-862.46K	-1.03M	-994.38K	-1.07M	-1.23M	-1.36M	-969.00K	-870.29K	-768.21K	-318.72K	4.87M	-26.35M	-24.46M	-19.16M	4.25M	10.27M	22.31M	-16.38M	-1.13M	-1.12M	7.88M	79.00K	-7.42M	-72.88M	-10.32M	-13.71M	-10.20M	-29.13M	-10.22M	-20.72M	-1.70M	-448.00K	-15.84M	621.00K	1.19M	45.10M
Diluted EPS	-	-	-	-	-	-	-	-	-	-	-	-	-0.06	-0.03	-0.02	-1.74	-1.42	-1.03	0.02	0.35	-0.01	-0.70	-0.04	-0.03	0.19	0.00	-	-1.72	-0.24	-0.32	-0.23	-0.67	-0.22	-0.45	-0.04	0.00	-0.33	0.01	0.02	0.91
R&D Expense	94.91K	160.53K	167.29K	192.78K	153.33K	322.17K	301.33K	329.53K	504.24K	599.03K	496.87K	286.75K	318.61K	293.09K	346.00K	325.00K	312.00K	359.00K	691.00K	1.03M	1.66M	1.48M	1.73M	1.99M	3.04M	3.22M	3.78M	3.43M	3.42M	4.15M	3.79M	3.74M	2.08M	2.03M	1.89M	1.44M	2.72M	2.71M	2.65M	2.96M

Profit & Loss (Annual)

Figures in USD.

Metric	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Revenue	2.08M	2.76M	5.66M	8.95M	6.19M	6.45M	8.23M	11.02M	19.74M	27.37M	48.09M	-	76.24M	68.02M	74.65M	96.21M
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	29.33M	26.70M	24.55M	34.10M
Gross Profit	856.39K	1.40M	2.29M	3.76M	3.04M	3.81M	4.78M	6.75M	13.53M	-	-	-	46.91M	41.32M	50.10M	62.12M
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	57.59M	60.72M	54.57M	78.72M
Operating Income	-1.39M	-1.21M	-942.24K	-285.36K	-3.14M	-5.02M	-4.85M	-1.06M	3.66M	-220.00K	-6.24M	-	-10.68M	-19.40M	-4.48M	-16.60M
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	5.79M	-7.10M	4.18M	-11.91M
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	-	-4.85M	-12.22M	-8.82M	-12.08M
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-	-5.24M	-64.00K	-38.00K	49.00K
Net Income	-1.98M	-1.96M	-1.66M	-1.08M	-3.22M	-4.21M	-6.88M	-2.52M	-25.00M	-1.66M	1.98M	-	-139.81M	-68.00M	-20.18M	-4.59M
Diluted EPS	-	-	-	-	-	-	-	-0.21	-1.56	-0.09	-0.06	-	-3.29	-1.55	-0.44	-0.10
R&D Expense	318.90K	516.45K	463.64K	487.82K	871.10K	1.38M	2.03M	1.19M	1.30M	3.17M	6.72M	11.82M	8.67M	5.51M	4.75M	7.57M

Balance Sheet (Annual)

Figures in USD.

Metric	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Jan 2018	Mar 2018	Jun 2018	Sep 2018	Dec 2018	Mar 2019	Jun 2019	Sep 2019	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Assets	-	1.31M	1.66M	3.17M	3.35M	16.07M	12.37M	7.93M	12.14M	-	12.29M	21.79M	46.45M	45.47M	48.07M	51.30M	83.79M	92.82M	234.83M	554.29M	450.23M	412.71M	399.49M	405.88M
Total Equity	-7.83M	-9.55M	-11.18M	-12.49M	-13.27M	13.94M	8.51M	3.17M	-9.53M	-9.53M	-4.25M	-12.94M	-6.50M	14.63M	-3.74M	2.07M	35.19M	43.32M	204.43M	478.05M	364.19M	337.66M	348.91M	371.89M
Cash & Equivalents	139.15K	3.21K	16.86K	196.48K	156.27K	2.54M	2.17M	1.41M	6.66M	-	7.03M	14.17M	32.38M	30.66M	31.82M	19.62M	21.20M	6.45M	90.40M	69.86M	19.44M	27.90M	91.54M	33.04M
Long Term Debt	-	-	-	-	-	-	-	4.25M	-	-	-	-	-	-	-	-	-	13.00K	655.00K	6.35M	23.79M	17.56M	5.00M	0
Total Liabilities	-	10.86M	12.84M	15.66M	16.62M	2.14M	2.51M	4.76M	2.05M	-	16.55M	34.73M	52.94M	30.84M	51.81M	49.23M	48.60M	49.36M	29.58M	76.24M	86.04M	75.05M	50.58M	34.00M
Current Liabilities	-	340.70K	579.25K	1.37M	1.63M	1.26M	1.73M	1.13M	1.51M	-	1.31M	1.66M	2.10M	1.94M	2.70M	3.16M	5.01M	7.67M	15.57M	42.70M	44.58M	42.18M	32.73M	22.98M

Cash Flows (Annual)

Figures in USD.

Metric	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Operating Cash Flow	-1.25M	-989.92K	854.93K	146.01K	-3.16M	-4.97M	-4.33M	605.00K	2.35M	1.21M	6.64M	-4.59M	-8.49M	-12.50M	8.43M	20.11M
Investing Cash Flow	-28.41K	-91.43K	-1.15M	-236.67K	-8.14M	4.24M	392.79K	-144.00K	-6.50M	-27.02M	-24.71M	-13.19M	-58.12M	17.84M	58.30M	-71.54M
Financing Cash Flow	1.15M	1.09M	475.00K	50.46K	13.68M	368.75K	3.17M	4.80M	28.15M	1.60M	102.08M	-2.78M	16.32M	10.59M	-6.78M	-10.92M
Capital Expenditure	-28.41K	-93.53K	-1.15M	-236.67K	-589.68K	-134.01K	-143.53K	-144.00K	-500.00K	-675.00K	-1.96M	-8.38M	-10.38M	-6.38M	-3.23M	-9.48M
Free Cash Flow	-1.28M	-1.08M	-296.79K	-90.66K	-3.75M	-5.11M	-4.47M	461.00K	1.85M	538.00K	4.68M	-12.98M	-18.87M	-18.88M	5.20M	10.64M

Ratios (Annual)

Figures in %.

Metric	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Gross Margin %	41.1%	50.9%	40.5%	42.0%	49.0%	59.1%	58.1%	61.2%	68.5%	-	-	-	61.5%	60.7%	67.1%	64.6%
Operating Margin %	-67.0%	-43.8%	-16.6%	-3.2%	-50.7%	-77.8%	-59.0%	-9.6%	18.5%	-0.8%	-13.0%	-	-14.0%	-28.5%	-6.0%	-17.3%
Net Margin %	-95.3%	-70.9%	-29.3%	-12.1%	-52.0%	-65.3%	-83.6%	-22.8%	-126.7%	-6.1%	4.1%	-	-183.4%	-100.0%	-27.0%	-4.8%
ROE %	20.8%	17.5%	13.3%	8.2%	-23.1%	-49.5%	-217.1%	26.4%	-170.9%	-3.8%	1.0%	-	-38.4%	-20.1%	-5.8%	-1.2%
ROCE %	-144.0%	-111.7%	-52.2%	-16.5%	-21.2%	-47.1%	-71.4%	-9.9%	8.4%	-0.3%	-2.8%	-	-2.6%	-5.2%	-1.2%	-4.3%

Shareholding Pattern

Insiders

2.42%

Institutions

105.52%

Public Float

108.13%

Top Institutional Holders

#	Holder	% Held	Shares	Value
1	T. Rowe Price Investment Management, Inc.	13.82%	6.75M	$245.61M
2	Blackrock Inc.	13.05%	6.38M	$231.94M
3	Casdin Capital, LLC	9.53%	4.66M	$169.35M
4	Invesco Ltd.	4.59%	2.24M	$81.51M
5	Vanguard Capital Management LLC	4.02%	1.96M	$71.45M
6	State Street Corporation	3.39%	1.66M	$60.24M
7	Geode Capital Management, LLC	2.22%	1.09M	$39.54M
8	Massachusetts Financial Services Co.	2.21%	1.08M	$39.26M
9	Fred Alger Management, LLC	2.21%	1.08M	$39.20M
10	Dimensional Fund Advisors LP	2.14%	1.05M	$38.06M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for BLFS

Google News Fri, 04 Sep 2026

BioLife Solutions (NASDAQ:BLFS) Combines High Growth Momentum with a Breakout Setup - ChartMill

<a href="https://news.google.com/rss/articles/CBMizAFBVV95cUxQWjIyOEwyLVd0ejhDZTM2aUFxT2psWE9IMUVTNkw0eUVpYW54Ty1ZOXFOOE5kNC0xR0ZwXzV5clAyZGt6b2s2Y3VQTC1BVEl6YTZGYkw1OVhzcnhURXBORkFtN3dlQ3pzNDBNWV9BRUZJX2I1ZlBxUVQ4bkx6Q2I4UC1jR0ZuR2FyNUZfdV…

Google News Fri, 04 Sep 2026

Diamond Hill Bets on BioLife Solutions’ (BLFS) High Switching Cost - Yahoo Finance

<a href="https://news.google.com/rss/articles/CBMinAFBVV95cUxPZWcxdFpFY0JHWXpvU1hPT0tpMkxsa1NGQnd1aTNwTk4wSGd0OFpxWW1Uc0R6LVp6d2dRMmxjTkE1RXhaSXNnMW5zckFVZ05Uc1I2cDN0bjFoY3d3TkF3X0dGNkUxQVV4YXBfeTlOZmtBc290V3Z6Tl9rdk15bFp6dDMxa3ZacjV1bFdqTm…

Google News Sat, 05 Sep 2026

Does Diamond Hill’s New BLFS Stake Elevate BioLife Solutions’ Switching-Cost Moat Or Just Spotlight It? - simplywall.st

<a href="https://news.google.com/rss/articles/CBMi5AFBVV95cUxQUmVzbnlaSWxUUV9xdjNoNjQ2Ul9SQWhVaTBEUEsyMHE0N3REbnFhZW9VWVFRSU9PcXlLWTRycThnbGlZaWlDWm4zSlVxOENHaTBFdDZVQlJJTUNyeUNxVUlhOHhSZ0pkeDJhMElnQXIxQjdtalJsMFV0SXdsR3QyNXI0MEozd2tfQlA3SU…

Google News Sat, 29 Aug 2026

BLFS Stock Alert: Halper Sadeh LLC is Investigating Whether BioLi - The National Law Review

<a href="https://news.google.com/rss/articles/CBMiswFBVV95cUxQbnAzWXRMTjJoSjFJb0xiaUcxeERUU09sZzZCUnJ2TERoV25lSy1TTFl0d0ZLOUJrc2FyN0c4UmRKYWJNb2pXUk9RYnUwekF6NU41WW1tWXM1VEdsdGstX1NOeXNlc0IzaHBoNDJ1NERibE1kZ0VDY3o3MEdkN0hfNUJtbldfeUhKZlFRdF…

Google News Fri, 04 Sep 2026

[DEFM14A] BIOLIFE SOLUTIONS INC Merger Proxy Statement - Stock Titan

<a href="https://news.google.com/rss/articles/CBMitAFBVV95cUxQNF83NXpJWS1kcWJLZ3F3VTJwd0NSZnlmX1FpaTdITHdKMDM4MWMwUVh0M1MtVi0zaS12WWF5QlhLemRuYTlwc0xEc3AtbVFiWTJ5WjR5bTdFWnJSbUdGLUZHYVdxd2xjMEtySlV2VWhKVFRETXRvRGI4aVFNS2haYWhEY2xYbUJFT1VJZ3…

Google News Wed, 22 Jul 2026

Why BioLife Solutions (BLFS) Stock Is Up Today - quiverquant.com

<a href="https://news.google.com/rss/articles/CBMiiwFBVV95cUxOYWI0QUJvSWlpV2VvVm81dE1Qbk5Ba2hpNzdQako0NTBUTjZRM0JSd29PMDhmMzRmTzl2Rm5IZFI3V1dpMXQyZnVGczdJRkVNSzFIOXJHX1RNOE11MXJPRERZYWFGZ29XSVZoMTEzZHRjUzgzcEZNZDItY2U3YVV4TTFoTEV3VUpLU3Qw?o…

BLFS — Frequently Asked Questions

What is the current share price of BioLife Solutions, Inc. (BLFS)?

As of 2026-09-07 16:24 PDT, BioLife Solutions, Inc. (BLFS) trades at $35.25 on NasdaqCM. Its 52-week range is $18.15 to $37.22.

What is the market capitalisation of BLFS?

BioLife Solutions, Inc. (BLFS) has a market capitalisation of $1.72B on NasdaqCM.

What is the P/E ratio of BLFS?

BLFS trades at a trailing price-to-earnings (P/E) ratio of -146.88. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 4.49.

What is the return on equity (ROE) of BLFS?

BLFS has a return on equity (ROE) of -3.09%. Its return on capital employed (ROCE) is -4.34%.

Is BLFS a good stock to buy?

This page provides a data-driven analysis of BioLife Solutions, Inc. (BLFS), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks

BioLife Solutions, Inc. BLFS R2KR3KPHARMA

Company Overview

Why Investors Should Care

Recent Developments

Growth & Price Performance

Compounded Sales Growth

Stock Price Performance

Price Chart

Technical Trend

Fundamental Growth Charts

PROS

CONS

Valuation

Growth (CAGR)

Profitability & Returns

Balance Sheet & Liquidity

Ownership

Financial Snapshot

Peer comparison

Quarterly Results

Profit & Loss (Annual)

Balance Sheet (Annual)

Cash Flows (Annual)

Ratios (Annual)

Shareholding Pattern

Top Institutional Holders

Analyst View

Latest News

BioLife Solutions (NASDAQ:BLFS) Combines High Growth Momentum with a Breakout Setup - ChartMill

Diamond Hill Bets on BioLife Solutions’ (BLFS) High Switching Cost - Yahoo Finance

Does Diamond Hill’s New BLFS Stake Elevate BioLife Solutions’ Switching-Cost Moat Or Just Spotlight It? - simplywall.st

BLFS Stock Alert: Halper Sadeh LLC is Investigating Whether BioLi - The National Law Review

[DEFM14A] BIOLIFE SOLUTIONS INC Merger Proxy Statement - Stock Titan

Why BioLife Solutions (BLFS) Stock Is Up Today - quiverquant.com

BLFS — Frequently Asked Questions

What is the current share price of BioLife Solutions, Inc. (BLFS)?

What is the market capitalisation of BLFS?

What is the P/E ratio of BLFS?

What is the return on equity (ROE) of BLFS?

Is BLFS a good stock to buy?

Explore More